Company
Headquarters: LA Jolla, CA, United States
Employees: 138
CEO: Mr. Andrew Spaventa
$49.9 Million
USD as of Jan. 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $201.46 B |
| EssilorLuxottica SA | $144.43 B |
| Becton, Dickinson and Company | $55.63 B |
| HOYA Corp | $50.63 B |
| Alcon Inc. | $39.46 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
Singular Genomics Systems, Inc. has the following listings and related stock indices.
Stock: NASDAQ: OMIC